Assessment of fixed‐duration therapies for treatment‐naïve <scp>Waldenström</scp> macroglobulinemia

Jithma P. Abeykoon(Mayo Clinic), Prashant Kapoor, Thomas E. Witzig(WinnMed), David Dingli, Jonas Paludo(WinnMed), Asher Chanan‐Khan(WinnMed), Francis K. Buadi, Morie A. Gertz(Medical University of South Carolina), Taimur Sher(Mayo Clinic in Florida), Rebecca L. King(Mayo Clinic in Arizona), Robert A. Kyle(Mayo Clinic), Carrie A. Thompson(Mayo Clinic), Thomas M. Habermann(Mayo Clinic in Arizona), Shaji Kumar(Mayo Clinic), Craig B. Reeder(Mayo Clinic in Arizona), Ronald S. Go(Mayo Clinic), Sikander Ailawadhi(Jacksonville College), Allison Rosenthal(Mayo Clinic Hospital), Stephen M. Ansell(Mayo Clinic), Grzegorz S. Nowakowski(Université Claude Bernard Lyon 1), S. Vincent Rajkumar(WinnMed), Wilson I. Gonsalves(Mayo Clinic in Arizona), David J. Inwards(Mayo Clinic), Patricia T. Greipp(Mayo Clinic), Saurabh Zanwar(Mayo Clinic), Martha Q. Lacy(Mayo Clinic), Eli Muchtar(Mayo Clinic), Rong He(Mayo Clinic), Gita Thanarajasingam(Mayo Clinic in Arizona), Angela Dispenzieri(Mayo Clinic), Vivek Roy(Jacksonville College), Jeremy T. Larsen(City of Hope)
American Journal of Hematology
April 29, 2021
Cited by 25


Related Papers